What's Causing the M&A Frenzy in Pharmaceuticals?

The video discusses the aggressive acquisition strategies of pharmaceutical companies, focusing on Activists and their continuous deal-making. It highlights the industry's trend of buying pipelines and growth due to older drugs losing patent protection. The video also covers the impact of new tax rules on these deals and the record-breaking $450 billion in deals announced or completed. Allergan's defensive strategies against being acquired by Valeant are also explored, illustrating the competitive nature of the industry. Overall, the video emphasizes the significant impact of these activities on pharma stocks.

What strategies are companies using to acquire growth in the pharmaceutical industry?

What record was set in terms of deal value in the pharmaceutical industry this year?

How has the corporate tax rate influenced pharmaceutical deals?

What are the potential defensive strategies that companies like Allergan might consider?

Discuss the implications of smaller pharmaceutical companies being acquired by larger ones.